skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Resultados 1 2 3 4 5 next page
Mostrar Somente
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis

Rudwaleit, M. ; Rosenbaum, J. T. ; Landewé, R. ; Marzo‐Ortega, H. ; Sieper, J. ; van der Heijde, D. ; Davies, O. ; Bartz, H. ; Hoepken, B. ; Nurminen, T. ; Deodhar, A.

Arthritis care & research (2010), 2016-06, Vol.68 (6), p.838-844 [Periódico revisado por pares]

United States: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
2
Effect of Certolizumab Pegol Over Ninety‐Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
Effect of Certolizumab Pegol Over Ninety‐Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effect of Certolizumab Pegol Over Ninety‐Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial

Sieper, J. ; Landewé, R. ; Rudwaleit, M. ; Heijde, D. ; Dougados, M. ; Mease, P. J. ; Braun, J. ; Deodhar, A. ; Kivitz, A. ; Walsh, J. ; Hoepken, B. ; Nurminen, T. ; Maksymowych, W. P.

Arthritis & rheumatology (Hoboken, N.J.), 2015-03, Vol.67 (3), p.668-677 [Periódico revisado por pares]

United States: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
3
Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis
Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis

van der Heijde, D. ; Deodhar, A. ; Fleischmann, R. ; Mease, P. J. ; Rudwaleit, M. ; Nurminen, T. ; Davies, O.

Arthritis care & research (2010), 2017-07, Vol.69 (7), p.1030-1039 [Periódico revisado por pares]

United States: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
4
Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial
Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial

Walsh, J. A. ; Gottlieb, A. B. ; Hoepken, B. ; Nurminen, T. ; Mease, P. J.

Clinical rheumatology, 2018-12, Vol.37 (12), p.3285-3296 [Periódico revisado por pares]

London: Springer London

Texto completo disponível

Citações Citado por
5
THU0380 A Single Determination of C-Reactive Protein Does Not Suffice To Declare A Patient with A Diagnosis of Axial SPA “CRP-Negative”
THU0380 A Single Determination of C-Reactive Protein Does Not Suffice To Declare A Patient with A Diagnosis of Axial SPA “CRP-Negative”
Material Type:
Artigo 		Adicionar ao Meu Espaço

THU0380 A Single Determination of C-Reactive Protein Does Not Suffice To Declare A Patient with A Diagnosis of Axial SPA “CRP-Negative”

Landewé, R. ; Nurminen, T. ; Davies, O. ; Turina, M. ; Baeten, D.

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.325-325 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
6
Search for KPNA7 cargo proteins in human cells reveals MVP and ZNF414 as novel regulators of cancer cell growth
Search for KPNA7 cargo proteins in human cells reveals MVP and ZNF414 as novel regulators of cancer cell growth
Material Type:
Artigo 		Adicionar ao Meu Espaço

Search for KPNA7 cargo proteins in human cells reveals MVP and ZNF414 as novel regulators of cancer cell growth

Vuorinen, Elisa M. ; Rajala, Nina K. ; Rauhala, Hanna E. ; Nurminen, Anssi T. ; Hytönen, Vesa P. ; Kallioniemi, Anne

Biochimica et biophysica acta. Molecular basis of disease, 2017-01, Vol.1863 (1), p.211-219 [Periódico revisado por pares]

Netherlands: Elsevier B.V

Texto completo disponível

Citações Citado por
7
Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial
Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial

Walsh, J. A. ; Gottlieb, A. B. ; Hoepken, B. ; Nurminen, T. ; Mease, P. J.

Clinical rheumatology, 2018-12, Vol.37 (12), p.3297-3297 [Periódico revisado por pares]

London: Springer London

Texto completo disponível

Citações Citado por
8
SAT0403 Further Analysis of Psoriatic Arthritis Disease Activity Score (PASDAS) and Composite Psoriatic Disease Activity Index (CPDAI) Using Data from A Placebo-Controlled TRIAL of Certolizumab Pegol in Psoriatic Arthritis
SAT0403 Further Analysis of Psoriatic Arthritis Disease Activity Score (PASDAS) and Composite Psoriatic Disease Activity Index (CPDAI) Using Data from A Placebo-Controlled TRIAL of Certolizumab Pegol in Psoriatic Arthritis
Material Type:
Artigo 		Adicionar ao Meu Espaço

SAT0403 Further Analysis of Psoriatic Arthritis Disease Activity Score (PASDAS) and Composite Psoriatic Disease Activity Index (CPDAI) Using Data from A Placebo-Controlled TRIAL of Certolizumab Pegol in Psoriatic Arthritis

Helliwell, P. ; Mease, P.J. ; Nurminen, T. ; FitzGerald, O.

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.740-740 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
9
SAT0338 Disease Activity and Clinical Response Early in the Course of Treatment PREDICT Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
SAT0338 Disease Activity and Clinical Response Early in the Course of Treatment PREDICT Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Material Type:
Artigo 		Adicionar ao Meu Espaço

SAT0338 Disease Activity and Clinical Response Early in the Course of Treatment PREDICT Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol

van der Heijde, D. ; Deodhar, A. ; Davies, O. ; Nurminen, T. ; Rudwaleit, M.

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.714-715 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
10
SAT0362 Certolizumab Pegol Rapidly Reduces Peripheral Enthesitis and the Incidence of Tender and Swollen Joints in Patients with Active Axial Spondyloarthritis, Including Both Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
SAT0362 Certolizumab Pegol Rapidly Reduces Peripheral Enthesitis and the Incidence of Tender and Swollen Joints in Patients with Active Axial Spondyloarthritis, Including Both Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Material Type:
Artigo 		Adicionar ao Meu Espaço

SAT0362 Certolizumab Pegol Rapidly Reduces Peripheral Enthesitis and the Incidence of Tender and Swollen Joints in Patients with Active Axial Spondyloarthritis, Including Both Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

Mease, P.J. ; Dougados, M. ; Davies, O. ; Nurminen, T. ; Sieper, J.

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.724-725 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (101)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (107)
  2. Anais de Congresso  (5)
  3. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1975  (12)
  2. 1975Até1991  (19)
  3. 1992Até2002  (13)
  4. 2003Até2014  (31)
  5. Após 2014  (40)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.